- Home
- BCYC vs DGICB Comparison
BCYC vs DGICB Comparison
Compare BCYC & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- DGICB
- Stock Information
- Founded
- BCYC 2009
- DGICB 1986
- Country
- BCYC United Kingdom
- DGICB United States
- Employees
- BCYC N/A
- DGICB N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- DGICB Property-Casualty Insurers
- Sector
- BCYC Health Care
- DGICB Finance
- Exchange
- BCYC Nasdaq
- DGICB Nasdaq
- Market Cap
- BCYC 492.1M
- DGICB 562.0M
- IPO Year
- BCYC 2019
- DGICB N/A
- Fundamental
- Price
- BCYC $7.96
- DGICB $16.84
- Analyst Decision
- BCYC Buy
- DGICB
- Analyst Count
- BCYC 11
- DGICB 0
- Target Price
- BCYC $22.91
- DGICB N/A
- AVG Volume (30 Days)
- BCYC 303.4K
- DGICB 966.0
- Earning Date
- BCYC 10-30-2025
- DGICB 10-30-2025
- Dividend Yield
- BCYC N/A
- DGICB 3.91%
- EPS Growth
- BCYC N/A
- DGICB 965.80
- EPS
- BCYC N/A
- DGICB 2.34
- Revenue
- BCYC $19,281,000.00
- DGICB $993,644,532.00
- Revenue This Year
- BCYC N/A
- DGICB $2.26
- Revenue Next Year
- BCYC N/A
- DGICB $3.46
- P/E Ratio
- BCYC N/A
- DGICB $8.40
- Revenue Growth
- BCYC N/A
- DGICB 3.36
- 52 Week Low
- BCYC $6.10
- DGICB $12.61
- 52 Week High
- BCYC $28.67
- DGICB $20.46
- Technical
- Relative Strength Index (RSI)
- BCYC 58.20
- DGICB 58.37
- Support Level
- BCYC $7.40
- DGICB $15.73
- Resistance Level
- BCYC $8.69
- DGICB $16.40
- Average True Range (ATR)
- BCYC 0.38
- DGICB 0.14
- MACD
- BCYC 0.11
- DGICB -0.09
- Stochastic Oscillator
- BCYC 62.23
- DGICB 51.15
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.